ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Avexis, Inc. (delisted)

Avexis, Inc. (delisted) (AVXS)

217.83
0.00
(0.00%)
Closed November 03 4:00PM
0.00
0.00
(0.00%)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
217.83
Bid
9.50
Ask
217.96
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
217.83
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

AVXS Latest News

AveXis Reports First Quarter 2018 Financial and Operating Results

-- Significant progress across operating functions including licensing, clinical trials and regulatory interactions -- -- AVXS-101 pre-BLA meeting with FDA is scheduled to be held in June 2018...

AveXis Provides Update on Proposed Acquisition by Novartis AG

CHICAGO, May 01, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...

AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3

CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...

AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-10...

– A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial – – All patients in the therapeutic dose cohort in the Phase 1 trial...

AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology

CHICAGO, April 19, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...

WEISSLAW LLP Investigates AveXis Inc. Acquisition

WEISSLAW LLP Investigates AveXis Inc. Acquisition PR Newswire NEW YORK, April 11, 2018 NEW YORK, April 11, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty...

What's News: Business & Finance -- WSJ

This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (April 10, 2018). The Justice...

Gene-Therapy Stocks Get Boost as Analysts Speculate Novartis' Next Target -- Market Mover

Gene-therapy companies got a boost during Monday trading after Novartis AG's (NVS) $8.7 billion deal to buy AveXis Inc. (AVXS), making good on CEO Vasant Narasimhan's promise to strike...

Novartis Buying AveXis for $8.7 Billion -- Deal Digest

By Cara Lombardo ACQUIRER: Switzerland-based Novartis AG (NVS) TARGET: Illinois-based AveXis Inc. (AVXS) PRICE: $8.7 billion in cash. Novartis will pay AveXis shareholders $218 a share, about an...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VSTEVast Renewable Ltd
$ 4.98
(149.00%)
68.54M
INVZWInnoviz Technologies Ltd
$ 0.096
(96.71%)
22.71k
CDXCChromaDex Corporation
$ 5.87
(68.19%)
37.88M
ATHAAthira Pharma Inc
$ 0.606
(41.56%)
239.63M
TILEInterface Inc
$ 23.24
(33.03%)
2.16M
EPIXESSA Pharma Inc
$ 1.45
(-72.12%)
34.3M
ELABElevai Labs Inc
$ 0.0288
(-51.19%)
202.28M
OSTOstin Technology Group Company Ltd
$ 0.275
(-45.00%)
2.27M
LXRXLexicon Pharmaceuticals Inc
$ 1.23
(-36.92%)
21M
VCIGVCI Global Ltd
$ 0.0583
(-27.58%)
26.57M
ATHAAthira Pharma Inc
$ 0.606
(41.56%)
239.63M
SQQQProShares UltraPro Short QQQ
$ 7.44
(-2.11%)
216.16M
NVDANVIDIA Corporation
$ 135.40
(1.99%)
209.27M
ELABElevai Labs Inc
$ 0.0288
(-51.19%)
202.28M
INTCIntel Corporation
$ 23.20
(7.81%)
173.47M

Discussion

View Full Feed
Cologne9672 Cologne9672 2 minutes ago
Wow! I’m speechless at the recent posts. Why would anyone not keep track of the things that are being said on this message board. The level of insanity must be studied.
CRGP
Aimless Blade Aimless Blade 3 minutes ago
Another material I wasn’t aware of (dysprosium used to make capacitors) is sourced 99.9% from China…

Sorry about the pay wall article…
https://www.nytimes.com/2024/10/26/business/china-critical-minerals-semiconductors.html
LWLG
Debunkinator Debunkinator 4 minutes ago
This will be all tonight😉
Christmas eve as a kid, lying in bed trying to force yourself to sleep so morning will come--But it's hard, as you are wondering what's in them boxes under the tree. $$$ Weeeeeeeeeeeeeeee
#ASII We have been working real hard and excited to share a MAJ
ASII
Risk Risk 4 minutes ago
Thanks R2R. 
AFFU
theorysuit theorysuit 6 minutes ago
Man if there ain't regulatory news before the end of Q1/2025, you better just run away because it won't be a happy ending.
NWBO
wagner wagner 6 minutes ago
I guess 99 % of readers agree with you

We are heading towards 1 billion pre split... 
And they deliver a 🙄👀🙄 rolling eyes,
Spac was a historical mistake from my point of view. 

But let's see what's in the cards next year..... 10s ba
NB
louieforpar louieforpar 8 minutes ago
Now that we have turned our clocks back,come Tuesday let's not turn our country back 50 years. 

Project 2025:

DJT
Rocketred Rocketred 8 minutes ago
Midas Letter a good one should bring in new buyers
PVGDF
Rocketred Rocketred 9 minutes ago
Yes can't wait till hole 1 comes out it will be big
PVGDF
money6870 money6870 10 minutes ago
Put them up at the ask somebody will buy them.
APRU
Rocketred Rocketred 10 minutes ago
PAU PVGDF Midas letter Interview https://www.youtube.com/watch?v=PonngVky1jI
PVGDF
oystersnbeer oystersnbeer 11 minutes ago
I don't care if you think I'm Satan reincarnated"

https://youtu.be/ERAo3O8R8fs?feature=shared
EZ2 EZ2 12 minutes ago
Go DJT !!!! :-)
DJT
ListenToMe ListenToMe 12 minutes ago
And you're Wrong as usual 🙄
PSIL
eyal2 eyal2 13 minutes ago
Unbelievable
If this is indeed true , it is froud  of the highest order
We have to DEMAND officially immediate  response from the company 
MWWC
KVM KVM 13 minutes ago
No matter how I spin #s not good. Veri did approximately $50 mil in revs without Veri 1 revs for 1st half of 2024. Now guiding for $44 mil in revs in 2nd half. What the hell happened. 2nd half was suppose to be way better than 1st half. For 2nd half they guided just on 8/7 for $59 mil in revs.They b
VERI
1vman 1vman 13 minutes ago
***** Millions in toxic notes owed on MJNA - dats why these otc stinky pinkies trade in da gutter

1. SET BUY LOW shares
2. SET SELLs LOW sells at end of closes with price limit ! In time .0001will come.
MJNA is a horrible company.
Best to the Xperienced investors
MJNA
EZ2 EZ2 14 minutes ago
I boxed 9-11 11-9 ( Porsche luck ) ~~~~ $29.80 bought pizza ! :-)

I watched most all the races Friday and Saturday. Some great races, but nearly impossible to handicap.

Some really huge payouts ------ wonder if anyone hit that .50 Pick 5 ???? Life changing pa
davidsson10 davidsson10 16 minutes ago
Haven't yet heard about Goldbelly?

Well, here you go (and bring your appetite with you).....https://www.goldbelly.com/
Huggy Bear Huggy Bear 16 minutes ago
Take a glance at OXSQ. I'm heavily vested and adding regularly, especially at the current price range.
BLX
jour_trader jour_trader 16 minutes ago
I'd say around 60-7 style="font-size: 1em"0 cents for now, assuming a decent penetration of the opioid markets we're launching into soon. However, if we get Vyvanse approval, add a dollar to the share price near term. Huge opportunity there. 
style="font-size: 1em"

ELTP
frrol frrol 18 minutes ago
Analogous to the APOE allele studies, a possibly worthwhile study would be SIGMAR1 status in AD vs non-AD geriatric populations. The study would explore whether S1 status is correlated to susceptibility to AD.

AD is multi-factorial, but the APOE status (specifically APOE4) shows a ve
AVXL

Your Recent History

Delayed Upgrade Clock